PSMA-Targeted Imaging Agent Posluma Approved to Aid in Prostate Cancer Detection
The approval was based on data from the LIGHTHOUSE and SPOTLIGHT clinical trials.
The approval was based on data from the LIGHTHOUSE and SPOTLIGHT clinical trials.
Transient clinically meaningful decline noted in EPIC hormonal and sexual domains with total androgen suppression added to radiation
The increasing number of indications for second-generation antiandrogens may result in a large group of men at risk for toxic effects, according to investigators.
Study findings highlight the need for earlier mCSPC treatment intensification by urologists and oncologists.
The phase 3 EMBARK trial involved more than 200 global sites and had 8 years of follow-up.
NRG 0815 is a “landmark” study investigating the role of short-term androgen deprivation therapy added to modern, dose-escalated radiation to treat intermediate-risk prostate cancer.
Researchers say they have identified 4 subtypes of prostate cancer with distinct biological and clinical features, and these subtypes may respond differently to treatment.
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
Investigators report results from the phase 3 randomized EMBARK trial.
Findings suggest link to more aggressive disease among estrogen users, but researchers say larger studies needed